EK
EKF.LSE EKF Diagnostics Holdings Plc
- Market cap
- GBX 100M
- P/E
- 23.4x
- P/B
- 1.43x
- ROE
- 13.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is EKF.LSE undervalued?
Graham numberEKF.LSE trades 21.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EKF Diagnostics Holdings Plc fundamental analysis
No fundamental analysis for EKF Diagnostics Holdings Plc yet.
EKF Diagnostics Holdings Plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EKF Diagnostics Holdings Plc
EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm analyzer; Hemo Control, a hemoglobin analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such…
Full company profileEKF Diagnostics Holdings Plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
EKF Diagnostics Holdings Plc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 38.6M | 41.6M | 42.5M | 44.9M | 65.3M | 81.8M | 66.6M | 52.6M | 50.2M | 51.6M | 100M |
| Gross Profit | 18.3M | 22.9M | 22.7M | 23.7M | 37.4M | 39.4M | 24.0M | 23.9M | 21.5M | 26.5M | 53.1M |
| Operating Income | -327K | 4.73M | 12.2M | 5.78M | 16.9M | 21.7M | 7.56M | 2.08M | 6.46M | 6.98M | 14.2M |
| EBITDA | 4.46M | 9.04M | 16.2M | 10.0M | 20.0M | 27.4M | -2.18M | 7.68M | 11.2M | 12.4M | 23.3M |
| Net Income | -18.0K | 2.72M | 10.1M | 3.68M | 11.1M | 15.9M | -10.1M | 2.35M | 6.24M | 2.12M | 9.28M |
| EPS | 0.00 | 0.01 | 0.02 | 0.01 | 0.02 | 0.03 | -0.02 | 0.01 | 0.01 | 0.00 | 0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 82.4M | 77.2M | 81.4M | 87.1M | 101M | 115M | 89.3M | 80.8M | 81.7M | 81.1M | 82.3M |
| Total Liabilities | 21.5M | 16.7M | 17.5M | 16.0M | 23.1M | 20.4M | 14.8M | 12.6M | 8.53M | 10.9M | 10.8M |
| Shareholders' Equity | 60.5M | 60.0M | 63.5M | 70.6M | 77.6M | 94.1M | 73.3M | 67.1M | 72.3M | 69.1M | 70.4M |
| Cash & Short-term Investments | 7.87M | 8.20M | 10.3M | 12.1M | 21.9M | 20.3M | 11.6M | 6.02M | 13.0M | 15.8M | 16.0M |
| Total Debt | 5.72M | 1.21M | 880K | 1.66M | 1.96M | 3.47M | 1.55M | 4.10M | 1.32M | 1.39M | 1.47M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 8.94M | 9.05M | 8.32M | 5.10M | 13.8M | 10.2M | 9.69M | 6.31M | 13.7M | 9.71M | 13.3M |
| Capital Expenditure | 1.92M | 2.21M | 1.85M | 2.38M | 2.65M | 5.65M | 5.83M | 6.98M | 2.25M | 1.53M | 3.46M |
| Free Cash Flow | 7.02M | 6.84M | 6.47M | 2.73M | 11.2M | 4.59M | 3.86M | -664K | 11.4M | 8.18M | 9.82M |
| Ratios | |||||||||||
| ROE | 0.0% | 4.5% | 15.9% | 5.2% | 14.3% | 16.8% | -13.8% | 3.5% | 8.6% | 3.1% | 13.2% |
| ROA | 0.0% | 3.5% | 12.4% | 4.2% | 11.0% | 13.8% | -11.3% | 2.9% | 7.6% | 2.6% | 11.3% |
| Net Profit Margin | 0.0% | 6.5% | 23.8% | 8.2% | 17.0% | 19.4% | -15.2% | 4.5% | 12.4% | 4.1% | 9.3% |
| Debt to Equity | 0.09x | 0.02x | 0.01x | 0.02x | 0.03x | 0.04x | 0.02x | 0.06x | 0.02x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
EKF Diagnostics Holdings Plc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Nov 2, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | GBP 5.45M | 0.01 | 231.5% |
| 2022 | GBP 5.46M | 0.01 | - |
| 2021 | GBP 5.10M | 0.01 | 32.2% |
| 2020 | GBP 4.55M | 0.01 | 40.9% |
| 2019 | GBP 15.0K | 0.00 | 0.4% |
| 2018 | GBP 4.55M | 0.01 | 45.0% |
| 2017 | GBP 4.55M | 0.01 | 167.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns EKF Diagnostics Holdings Plc
- Insiders 3.94%
- Institutions 72.77%
- Public & others 23.29%
- Shares outstanding 428M
- Free float 352M
EKF Diagnostics Holdings Plc company profile
- Company name
- EKF Diagnostics Holdings Plc
- Ticker
- EKF.LSE
- ISIN
- GB0031509804
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 308
- Fiscal year end
- December
- Address
- Avon House, Cardiff, United Kingdom, CF64 2EZ
- Phone
- 44 29 2071 0570
- Website
- ekfdiagnostics.com
About EKF Diagnostics Holdings Plc
EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm analyzer; Hemo Control, a hemoglobin analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab HbA1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test HbA1c, fully automated hemoglobin A1c analyzer for the monitoring and management of diabetes; and STAT-Site W Beta-Hydroxybutyrate analyzer. In addition, the company offers Creamatocrit Plus, a breast milk analyzer; QuPID and True20 pregnancy tests; Lactate Scout Vet, a handheld lactate analyzer for veterinary care; Hemo Vet, a point-of-care hemoglobin and hematocrit analyzer; Lactate Scout Sport, a lactate analyzer for sports performance; Biosen series for sports; and EKF Link, a data management solution that integrates point-of-care analyzers. Further, it offers Beta-Hydroxybutyrate LiquiColor for monitoring ketosis; RaPET, a range of immunoassay kits; QuStick Strep A for Strep A infection treatment; Hema-Screen Lab Pack for detection of colorectal cancer; PrimeStore MTM, a molecular transport medium that preserves and stabilizes DNA and RNA; Uri-Trak 120M urine analyzer; and clinical chemistry reagents, controls, and standards. Additionally, the company provides precision fermentation, custom bioprocessing, and contract manufacturing solutions; and diagnostic enzymes that include arylacylamidase, beta-hydroxybutyrate dehydrogenase, and salicylate hydroxylase. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
EKF Diagnostics Holdings Plc management
3- Mr. Julian Huw Baines M.B.E.Executive Chairman · born 1964
- Mr. Gavin Joseph JonesCEO & Director · born 1980
- Ms. Helen Mary Kinsey Jones F.C.A.CFO & Director · born 1979